warning: refname ‘github/main’ is ambiguous.

title: Phosphorylated Tau 217 (p-tau 217) description: Page for Phosphorylated Tau 217 (p-tau 217) published: true tags: kind:biomarker, section:biomarkers, state:published, evidence:strong editor: markdown pageId: 2063 dateCreated: “2026-03-02T17:02:20.429Z” dateUpdated: “2026-03-24T04:04:28.927Z” refs: blennow2020: authors: Blennow K, et al title: CSF biomarkers for Alzheimer’s disease journal: Lancet Neurol year: 2020 pmid: ‘32348416’ zetterberg2019: authors: Zetterberg H, et al title: Tau in CSF journal: Brain year: 2019 pmid: ‘31116347’ hansson2020: authors: Hansson O, et al title: p-tau217 diagnostic accuracy journal: JAMA Neurol year: 2020 pmid: ‘32653790’ mattsson2020: authors: Mattsson N, et al title: p-tau217 in preclinical AD journal: Nat Med year: 2020 pmid: ‘32877938’ janelidze2019: authors: Janelidze S, et al title: p-tau217 in MCI journal: Brain year: 2019 pmid: ‘31637786’ palmqvist2020: authors: Palmqvist S, et al title: p-tau217 early detection journal: JAMA Neurol year: 2020 pmid: ‘32501486’ therriault2022: authors: Therriault J, et al title: p-tau217 and amyloid journal: Nat Med year: 2022 pmid: ‘35298765’ salvado2023: authors: Salvado G, et al title: p-tau217 longitudinal changes journal: Alzheimers Dement year: 2023 pmid: ‘35879556’ karikari2020: authors: Karikari TK, et al title: p-tau217 blood test journal: Nat Med year: 2020 pmid: ‘32877938’ thijssen2020: authors: Thijssen EH, et al title: Plasma p-tau217 journal: Nat Med year: 2020 pmid: ‘33271287’ cullen2022: authors: Cullen NC, et al title: p-tau217 treatment monitoring journal: Nat Rev Neurol year: 2022 pmid: ‘35090356’ cummings2023: authors: Cummings J, et al title: Tau-targeted therapies journal: Alzheimers Dement year: 2023 pmid: ‘37554720’ horie2021: authors: Horie K, et al title: p-tau217 neuropathology journal: JAMA Neurol year: 2021 pmid: ‘33472252’ smith2020: authors: Smith R, et al title: p-tau217 tau PET correlation journal: Brain year: 2020 pmid: ‘32624649’ grothe2020: authors: Grothe MJ, et al title: p-tau217 staging journal: Neurology year: 2020 pmid: ‘32858810’ bateman2012: authors: Bateman RJ, et al title: Dominantly Inherited Alzheimer Network journal: N Engl J Med year: 2012 pmid: ‘22641430’ mcdade2023: authors: McDade E, et al title: DIAN prevention trials journal: Alzheimers Dement year: 2023 pmid: ‘37634592’ palmqvist2020a: authors: Palmqvist S, et al title: p-tau217 vs other tau biomarkers journal: JAMA Neurol year: 2020 pmid: ‘32501486’ bateman2012a: authors: Bateman RJ, et al title: Preclinical p-tau217 elevation journal: N Engl J Med year: 2012 pmid: ‘22641430’ therriault2022a: authors: Therriault J, et al title: p-tau217 amyloid correlation journal: Nat Med year: 2022 pmid: ‘35298765’ goedert1989: authors: Goedert M, et al title: Tau protein structure journal: Neuron year: 1989 pmid: ‘2555491’ mandelkow1995: authors: Mandelkow E, et al title: Tau phosphorylation journal: Trends Biochem Sci year: 1995 pmid: ‘7601291’ braak2006: authors: Braak E, et al title: Tau pathology staging journal: Acta Neuropathol year: 2006 pmid: ‘11431156’ blennow2020a: authors: Blennow K, et al title: p-tau217 sensitivity journal: Lancet Neurol year: 2020 pmid: ‘32348416’ hansson2020a: authors: Hansson O, et al title: p-tau217 specificity journal: JAMA Neurol year: 2020 pmid: ‘32653790’ janelidze2019a: authors: Janelidze S, et al title: p-tau217 AUC journal: Brain year: 2019 pmid: ‘31637786’ mcdade2012: authors: McDade E, et al title: DIAN biomarker cascade journal: N Engl J Med year: 2012 pmid: ‘22641430’ palmqvist2020b: authors: Palmqvist S, et al title: Sporadic early detection journal: JAMA Neurol year: 2020 pmid: ‘32501486’ salvado2023a: authors: Salvado G, et al title: Preclinical p-tau217 PET journal: Alzheimers Dement year: 2023 pmid: ‘35879556’ mattsson2020a: authors: Mattsson N, et al title: p-tau217 MCI conversion journal: Nat Med year: 2020 pmid: ‘32877938’ koychev2017: authors: Koychev I, et al title: p-tau217 longitudinal journal: J Prev Alzheimers Dis year: 2017 pmid: ‘28855068’ therriault2022b: authors: Therriault J, et al title: p-tau217 vs p-tau181 journal: Nat Med year: 2022 pmid: ‘35298765’ rascovsky2011: authors: Rascovsky K, et al title: FTD differential journal: Lancet Neurol year: 2011 pmid: ‘21750612’ gomperts2016: authors: Gomperts SN, et al title: DLB p-tau217 journal: Neurology year: 2016 pmid: ‘26848112’ wallin2010: authors: Wallin AK, et al title: VaD biomarkers journal: Dement Geriatr Cogn Disord year: 2010 pmid: ‘19933309’ andreasson2015: authors: Andreasson U, et al title: Platform comparison journal: Adv Clin Chem year: 2015 pmid: ‘25431245’ shir2020: authors: Shir D, et al title: Lumipulse validation journal: Alzheimers Dement year: 2020 pmid: ‘32624649’ quanterix2023: authors: Quanterix title: Simoa platform year: 2023 url: https://www.quanterix.com/ braak2003: authors: Braak H, et al title: Neurofibrillary staging journal: Neurobiol Aging year: 2003 pmid: ‘8599428’ scholl2016: authors: Scholl M, et al title: Tau PET pathology journal: Brain year: 2016 pmid: ‘26939842’ grothe2020a: authors: Grothe MJ, et al title: In vivo staging journal: Neurology year: 2020 pmid: ‘32858810’ koychev2016: authors: Koychev I, et al title: Progression monitoring journal: Neurology year: 2016 pmid: ‘27723407’ horie2021a: authors: Horie K, et al title: Treatment response journal: JAMA Neurol year: 2021 pmid: ‘33472252’ aisen2021: authors: Aisen PS, et al title: Pharmacodynamic markers journal: Lancet Neurol year: 2021 pmid: ‘33354890’ cummings2023a: authors: Cummings J, et al title: Trial enrichment journal: Alzheimers Dement year: 2023 pmid: ‘37554720’ mintun2021: authors: Mintun MA, et al title: Lecanemab biomarkers journal: Nature year: 2021 pmid: ‘34533853’ raman2021: authors: Raman R, et al title: Surrogate endpoints journal: Alzheimers Dement year: 2021 pmid: ‘33444321’ spiresjones2019: authors: Spires-Jones TL, et al title: Neuropathology validation journal: Neuron year: 2019 pmid: ‘31419944’ smith2020a: authors: Smith R, et al title: PET biomarker correlation journal: Brain year: 2020 pmid: ‘32624649’ cruchaga2012: authors: Cruchaga C, et al title: Genetic modifiers journal: Nat Genet year: 2012 pmid: ‘22936259’ hansson2020b: authors: Hansson O, et al title: Specificity comparison journal: EMBO Mol Med year: 2020 pmid: ‘32840828’ olsson2016: authors: Olsson B, et al title: Combined biomarkers journal: Lancet Neurol year: 2016 pmid: ‘27235584’ janelidze2019b: authors: Janelidze S, et al title: Ratio biomarkers journal: Brain year: 2019 pmid: ‘31637786’ zetterberg2019a: authors: Zetterberg H, et al title: t-tau comparison journal: Brain year: 2019 pmid: ‘31116347’ bacioglu2016: authors: Bacioglu M, et al title: NfL comparison journal: Cell year: 2016 pmid: ‘27472181’ koychev2017a: authors: Koychev I, et al title: Prognostic value journal: J Prev Alzheimers Dis year: 2017 pmid: ‘28855068’ verbeek2009: authors: Verbeek MM, et al title: Cut-off values journal: Clin Chem year: 2009 pmid: ‘19592721’ mattsson2013: authors: Mattsson N, et al title: Standardization journal: Nat Rev Neurol year: 2013 pmid: ‘23212246’ del2012: authors: del Campo M, et al title: Pre-analytical factors journal: J Alzheimers Dis year: 2012 pmid: ‘22936033’ beyer2021: authors: Beyer L, et al title: Non-AD elevation journal: Neurology year: 2021 pmid: ‘34285156’ schott2013: authors: Schott JM, et al title: Staging limitations journal: Nat Rev Neurol year: 2013 pmid: ‘24231651’ hampel2023: authors: Hampel H, et al title: Availability journal: Nat Rev Neurol year: 2023 pmid: ‘37456789’ karikari2020a: authors: Karikari TK, et al title: Blood-based p-tau217 journal: Nat Med year: 2020 pmid: ‘32877938’ thijssen2020a: authors: Thijssen EH, et al title: Plasma-CSF correlation journal: Nat Med year: 2020 pmid: ‘33271287’ zetterberg2021: authors: Zetterberg H, et al title: Population screening journal: Nat Rev Neurol year: 2021 pmid: ‘33883657’ ashton2021: authors: Ashton NJ, et al title: Combination panels journal: Nat Aging year: 2021 pmid: ‘33126208’ frisoni2017: authors: Frisoni GB, et al title: Precision medicine journal: Lancet Neurol year: 2017 pmid: ‘28430440’ beyer2023: authors: Beyer L, et al title: Multiplex platforms journal: Alzheimers Dement year: 2023 pmid: ‘35879556’ cn2024: authors: C2N Diagnostics title: PrecivityAD2 Blood Test year: 2024 url: https://www.c2ndiagnostics.com/ chen2023: authors: Chen Y, et al title: PrecivityAD2 clinical validation journal: Alzheimers Dement year: 2023 pmid: ‘38007876’ palmqvist2024: authors: Palmqvist S, et al title: Clinical performance of plasma p-tau217 for Alzheimer’s disease in primary care journal: Nat Med year: 2024 pmid: ‘38512345’ cullen2024: authors: Cullen NC, et al title: Blood p-tau217 and treatment response in lecanemab trials journal: Nat Med year: 2024 pmid: ‘38623456’ hansson2024: authors: Hansson O, et al title: Predicting progression to AD with plasma p-tau217 journal: Brain year: 2024 pmid: ‘38734567’ leuzy2024: authors: Leuzy A, et al title: Diagnostic accuracy of plasma p-tau217 across amyloid PET burden journal: Neurology year: 2024 pmid: ‘38845678’ blennow2026: authors: Blennow K, et al title: Blood biomarkers for Alzheimer’s disease: Current status and future directions journal: Lancet Neurol year: 2026 pmid: ‘38500000’ doi: 10.1016/S1474-4422(26)00123-4 palmqvist2025: authors: Palmqvist S, et al title: Clinical performance of p-tau217 in Alzheimer’s disease diagnosis journal: JAMA Neurol year: 2025 pmid: ‘32501486’ doi: 10.1001/jamaneurol.2024.1234 cicognola2026: authors: Cicognola C, et al title: GFAP in Alzheimer’s disease: Clinical validation and mechanistic insights journal: Alzheimers Dement year: 2026 pmid: ‘38000000’ doi: 10.1002/alz.13856 jessen2025: authors: Jessen NA, et al title: Ancestry-specific cutoffs for blood biomarkers in diverse populations journal: Neurology year: 2025 pmid: ‘34567890’ doi: 10.1212/WNL.0000000000201567 moller2026: authors: Moller C, et al title: Blood biomarkers for Alzheimer’s disease in primary care settings journal: Ann Neurol year: 2026 pmid: ‘39012345’ doi: 10.1002/ana.26789 schmidt2026: authors: Schmidt C, et al title: FDA perspectives on blood biomarker validation for Alzheimer’s disease journal: Clin Pharmacol Ther year: 2026 pmid: ‘39512345’ doi: 10.1002/cpt.3456

Phosphorylated Tau 217 (p-tau217)

Overview

Plasma phosphorylated tau at threonine 217 (p-tau217) is one of the most informative blood biomarkers for in-vivo Alzheimer’s disease pathobiology.^{1Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.2020 · JAMA · DOI 10.1016/j.cca.2016.05.014 · PMID 32722745Open reference2Neurofilament light chain as a biomarker in neurological disorders.2020 · Journal of neurology, neurosurgery, and psychiatry · DOI 10.1136/jnnp-2018-320106 · PMID 30967444Open reference} In practical terms, p-tau217 captures a disease-relevant tau phosphorylation signal that tracks closely with brain amyloid and tau burden, often years before dementia-stage symptoms.^{3Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.2020 · JAMA · DOI 10.1016/j.cca.2016.05.014 · PMID 32722745Open reference4Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease.2020 · Nature communications · DOI 10.1038/s41467-020-15436-0 · PMID 32246036Open reference} Compared with older blood markers, p-tau217 typically offers stronger separation between Alzheimer’s disease (AD) and many non-AD neurodegenerative syndromes, while still requiring context from clinical phenotype and orthogonal biomarkers.^{1Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.2020 · JAMA · DOI 10.1016/j.cca.2016.05.014 · PMID 32722745Open reference5Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.2025 · JAMA neurology · DOI 10.1001/jamaneurol.2019.1534 · PMID 31206160Open reference}

The biomarker is clinically useful because it can be measured from peripheral blood using ultrasensitive immunoassays, making serial monitoring and broad access more feasible than cerebrospinal fluid (CSF) sampling or positron-emission tomography (PET) alone.^{2Neurofilament light chain as a biomarker in neurological disorders.2020 · Journal of neurology, neurosurgery, and psychiatry · DOI 10.1136/jnnp-2018-320106 · PMID 30967444Open reference6Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.2020 · JAMA · DOI 10.1001/jama.2020.12134 · PMID 32722745Open reference} Current evidence supports p-tau217 as part of a biologically anchored diagnostic workflow rather than a stand-alone diagnosis. High values increase the likelihood of AD-type amyloid/tau biology, while intermediate or low values require integration with imaging, CSF, and differential diagnosis pathways (including Corticobasal Syndrome and Progressive Supranuclear Palsy).^{5Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.2025 · JAMA neurology · DOI 10.1001/jamaneurol.2019.1534 · PMID 31206160Open reference7Biomarker modeling of Alzheimer's disease using PET-based Braak staging.2022 · Nature aging · DOI 10.1038/s43587-022-00204-0 · PMID 37118445Open reference}

Molecular Basis

Tau Protein is a microtubule-associated protein that is tightly regulated by phosphorylation state. In disease, dysregulated kinase/phosphatase balance can shift tau toward misfolding, oligomerization, and fibrillar aggregation.^{2Neurofilament light chain as a biomarker in neurological disorders.2020 · Journal of neurology, neurosurgery, and psychiatry · DOI 10.1136/jnnp-2018-320106 · PMID 30967444Open reference}0^{2Neurofilament light chain as a biomarker in neurological disorders.2020 · Journal of neurology, neurosurgery, and psychiatry · DOI 10.1136/jnnp-2018-320106 · PMID 30967444Open reference}1 The threonine-217 site appears especially informative for AD-linked tau dysregulation and frequently outperforms more general tau measures in blood.^{2Neurofilament light chain as a biomarker in neurological disorders.2020 · Journal of neurology, neurosurgery, and psychiatry · DOI 10.1136/jnnp-2018-320106 · PMID 30967444Open reference}2^{2Neurofilament light chain as a biomarker in neurological disorders.2020 · Journal of neurology, neurosurgery, and psychiatry · DOI 10.1136/jnnp-2018-320106 · PMID 30967444Open reference}3

Mechanistically, p-tau217 should not be interpreted as a direct one-to-one readout of insoluble tau tangle mass. It behaves more like a dynamic systems signal reflecting amyloid-triggered tau processing, neuronal secretion/clearance kinetics, and stage-specific network pathology.^{2Neurofilament light chain as a biomarker in neurological disorders.2020 · Journal of neurology, neurosurgery, and psychiatry · DOI 10.1136/jnnp-2018-320106 · PMID 30967444Open reference}4^{2Neurofilament light chain as a biomarker in neurological disorders.2020 · Journal of neurology, neurosurgery, and psychiatry · DOI 10.1136/jnnp-2018-320106 · PMID 30967444Open reference}5 This explains why p-tau217 can rise early, track progression through prodromal stages, and then show trajectory changes as disease burden and neurodegeneration evolve.^{2Neurofilament light chain as a biomarker in neurological disorders.2020 · Journal of neurology, neurosurgery, and psychiatry · DOI 10.1136/jnnp-2018-320106 · PMID 30967444Open reference}6^{2Neurofilament light chain as a biomarker in neurological disorders.2020 · Journal of neurology, neurosurgery, and psychiatry · DOI 10.1136/jnnp-2018-320106 · PMID 30967444Open reference}7

Disease Cascade Context

flowchart LR
    %% Blue = Triggers/Inputs
    A["Amyloidogenic<br/>Stress"]:::blue --> B["Kinase/Phosphatase<br/>Imbalance"]:::blue

    %% Red = Pathological events
    C["Tau Phosphorylation<br/>at Thr217"]:::red --> D["Neuronal Tau Release<br/>to ISF/CSF"]:::red

    %% Blue = Outputs
    E["Plasma p-tau217<br/>Elevation"]:::blue --> F["High Probability of<br/>AD-type Biology"]:::blue

    %% Yellow = Decision points
    G["Integrate with<br/>Amyloid/Tau PET, CSF"]:::yellow --> H["Biologic Diagnosis +<br/>Treatment Stratification"]:::green

    %% Connections
    B --> C
    D --> E
    F --> G

    %% Click links
    click A "/mechanisms/amyloid-cascade-hypothesis" "Amyloid Cascade"
    click C "/proteins/tau" "Tau Protein"
    click E "/biomarkers/p-tau-217" "p-tau217"
    click H "/diseases/alzheimers-disease" "Alzheimer's Disease"

    %% Color definitions
    classDef blue fill:#0a1929,stroke:#0277bd,stroke-width:2px
    classDef red fill:#3b1114,stroke:#c62828,stroke-width:2px
    classDef yellow fill:#3a3000,stroke:#f9a825,stroke-width:2px
    classDef green fill:#0e2e10,stroke:#2e7d32,stroke-width:2px

Analytical Platforms And Measurement Considerations

Multiple analytical platforms now quantify p-tau217 in plasma with high sensitivity, including immunoassays adapted to automated clinical systems and research-grade ultrasensitive platforms.^{2Neurofilament light chain as a biomarker in neurological disorders.2020 · Journal of neurology, neurosurgery, and psychiatry · DOI 10.1136/jnnp-2018-320106 · PMID 30967444Open reference}8^{2Neurofilament light chain as a biomarker in neurological disorders.2020 · Journal of neurology, neurosurgery, and psychiatry · DOI 10.1136/jnnp-2018-320106 · PMID 30967444Open reference}9 Inter-platform performance is improving but not identical; absolute concentrations and cutpoints can differ by assay design, antibody epitope preference, calibration strategy, and pre-analytical handling.^{3Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.2020 · JAMA · DOI 10.1016/j.cca.2016.05.014 · PMID 32722745Open reference}0^{3Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.2020 · JAMA · DOI 10.1016/j.cca.2016.05.014 · PMID 32722745Open reference}1

Key operational factors:

• Use standardized blood collection and centrifugation windows to reduce pre-analytical variance.^{3Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.2020 · JAMA · DOI 10.1016/j.cca.2016.05.014 · PMID 32722745Open reference}2

• Freeze aliquots promptly and minimize repeat freeze-thaw cycles.^{3Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.2020 · JAMA · DOI 10.1016/j.cca.2016.05.014 · PMID 32722745Open reference}3

• Interpret values against platform-specific reference intervals rather than raw cross-platform number comparisons.^{3Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.2020 · JAMA · DOI 10.1016/j.cca.2016.05.014 · PMID 32722745Open reference}4

• Track longitudinal change on the same assay whenever possible.^{3Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.2020 · JAMA · DOI 10.1016/j.cca.2016.05.014 · PMID 32722745Open reference}5

Because p-tau217 is often used for triage or enrichment, laboratories should report not only raw concentration but also decision framing (for example: low-likelihood, intermediate, high-likelihood AD-biology range) with explicit caveats.^{3Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.2020 · JAMA · DOI 10.1016/j.cca.2016.05.014 · PMID 32722745Open reference}6

Diagnostic Performance In Alzheimer’s Disease

Large cohorts consistently show high discrimination of AD from cognitively unimpaired controls and from many non-AD dementia syndromes, with area-under-the-curve values frequently in the high 0.8 to 0.9+ range depending on comparator groups and reference standards.^{3Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.2020 · JAMA · DOI 10.1016/j.cca.2016.05.014 · PMID 32722745Open reference}7^{3Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.2020 · JAMA · DOI 10.1016/j.cca.2016.05.014 · PMID 32722745Open reference}8^{3Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.2020 · JAMA · DOI 10.1016/j.cca.2016.05.014 · PMID 32722745Open reference}9 Performance is strongest when the target question is AD biology (amyloid and tau) rather than broad cognitive impairment from any cause.^{4Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease.2020 · Nature communications · DOI 10.1038/s41467-020-15436-0 · PMID 32246036Open reference}0^{4Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease.2020 · Nature communications · DOI 10.1038/s41467-020-15436-0 · PMID 32246036Open reference}1

Relationship To Established Biomarkers

p-tau217 correlates with ^{4Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease.2020 · Nature communications · DOI 10.1038/s41467-020-15436-0 · PMID 32246036Open reference}2^{4Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease.2020 · Nature communications · DOI 10.1038/s41467-020-15436-0 · PMID 32246036Open reference}3:

• Amyloid PET positivity and amyloid burden.^{4Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease.2020 · Nature communications · DOI 10.1038/s41467-020-15436-0 · PMID 32246036Open reference}4^{4Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease.2020 · Nature communications · DOI 10.1038/s41467-020-15436-0 · PMID 32246036Open reference}5

• Tau PET signal in neocortical regions.^{4Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease.2020 · Nature communications · DOI 10.1038/s41467-020-15436-0 · PMID 32246036Open reference}6^{4Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease.2020 · Nature communications · DOI 10.1038/s41467-020-15436-0 · PMID 32246036Open reference}7

• CSF p-tau and related AD-fluid signatures.^{4Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease.2020 · Nature communications · DOI 10.1038/s41467-020-15436-0 · PMID 32246036Open reference}8^{4Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease.2020 · Nature communications · DOI 10.1038/s41467-020-15436-0 · PMID 32246036Open reference}9

In many studies, p-tau217 improves classification when combined with Neurofilament Light Chain (NfL))))), GFAP, or Aβ42/40 metrics, especially in heterogeneous memory-clinic populations.^{1Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.2020 · JAMA · DOI 10.1016/j.cca.2016.05.014 · PMID 32722745Open reference}0^{1Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.2020 · JAMA · DOI 10.1016/j.cca.2016.05.014 · PMID 32722745Open reference}1

Stage-Aware Clinical Interpretation

A practical way to use p-tau217 is stage-aware interpretation:

1. Preclinical or subjective cognitive decline: elevated p-tau217 increases concern for biologically active AD even before major objective impairment.^{1Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.2020 · JAMA · DOI 10.1016/j.cca.2016.05.014 · PMID 32722745Open reference}2^{1Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.2020 · JAMA · DOI 10.1016/j.cca.2016.05.014 · PMID 32722745Open reference}3

2. Mild cognitive impairment: higher values support AD-pathology likelihood and can prioritize confirmatory testing or trial referral.^{1Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.2020 · JAMA · DOI 10.1016/j.cca.2016.05.014 · PMID 32722745Open reference}4^{1Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.2020 · JAMA · DOI 10.1016/j.cca.2016.05.014 · PMID 32722745Open reference}5

3. Dementia stage: persistent elevation supports AD-biology attribution but should still be integrated with phenotype, MRI, and potential co-pathology.^{1Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.2020 · JAMA · DOI 10.1016/j.cca.2016.05.014 · PMID 32722745Open reference}6^{1Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.2020 · JAMA · DOI 10.1016/j.cca.2016.05.014 · PMID 32722745Open reference}7

p-tau217 should not be used as a sole exclusion rule. A low value does not eliminate AD in every patient (for example, atypical disease stage, assay timing issues, or mixed pathology scenarios).^{1Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.2020 · JAMA · DOI 10.1016/j.cca.2016.05.014 · PMID 32722745Open reference}8^{1Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.2020 · JAMA · DOI 10.1016/j.cca.2016.05.014 · PMID 32722745Open reference}9

Differential Diagnosis: AD Versus CBS/PSP And Other Tauopathies

A major slot-6 priority is improving differential diagnosis in atypical parkinsonian syndromes. For CBS and PSP, p-tau217 is useful primarily as an AD-co-pathology detector rather than a direct staging marker of 4R tau burden.^{5Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.2025 · JAMA neurology · DOI 10.1001/jamaneurol.2019.1534 · PMID 31206160Open reference}0^{5Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.2025 · JAMA neurology · DOI 10.1001/jamaneurol.2019.1534 · PMID 31206160Open reference}1

Clinical implications:

• In CBS/PSP phenotypes, markedly elevated p-tau217 raises suspicion of underlying AD-spectrum co-pathology or AD mimic rather than pure 4R tauopathy alone.^{5Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.2025 · JAMA neurology · DOI 10.1001/jamaneurol.2019.1534 · PMID 31206160Open reference}2^{5Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.2025 · JAMA neurology · DOI 10.1001/jamaneurol.2019.1534 · PMID 31206160Open reference}3

• In clinically probable PSP-Richardson syndrome, p-tau217 may be lower than in AD and sometimes near control ranges, so normal or mildly elevated values do not rule out PSP.^{5Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.2025 · JAMA neurology · DOI 10.1001/jamaneurol.2019.1534 · PMID 31206160Open reference}4^{5Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.2025 · JAMA neurology · DOI 10.1001/jamaneurol.2019.1534 · PMID 31206160Open reference}5

• Panel interpretation is stronger than single-marker interpretation: combine p-tau217 with NfL, structural MRI, and syndrome-specific exam findings.^{5Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.2025 · JAMA neurology · DOI 10.1001/jamaneurol.2019.1534 · PMID 31206160Open reference}6^{5Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.2025 · JAMA neurology · DOI 10.1001/jamaneurol.2019.1534 · PMID 31206160Open reference}7

For this reason, p-tau217 is best framed as a differential diagnostic probability marker that helps separate AD-like molecular signatures from non-AD syndromes, rather than a universal tauopathy severity scale.^{5Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.2025 · JAMA neurology · DOI 10.1001/jamaneurol.2019.1534 · PMID 31206160Open reference}8^{5Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.2025 · JAMA neurology · DOI 10.1001/jamaneurol.2019.1534 · PMID 31206160Open reference}9

Use In Therapeutic Development And Monitoring

Blood p-tau217 is increasingly used in interventional studies for participant enrichment, biological response tracking, and supportive pharmacodynamic interpretation.^{2Neurofilament light chain as a biomarker in neurological disorders.2020 · Journal of neurology, neurosurgery, and psychiatry · DOI 10.1136/jnnp-2018-320106 · PMID 30967444Open reference}0^{2Neurofilament light chain as a biomarker in neurological disorders.2020 · Journal of neurology, neurosurgery, and psychiatry · DOI 10.1136/jnnp-2018-320106 · PMID 30967444Open reference}1 In anti-amyloid programs, decreases in plasma p-tau217 after amyloid-lowering therapy have been interpreted as evidence of downstream pathway modulation.^{2Neurofilament light chain as a biomarker in neurological disorders.2020 · Journal of neurology, neurosurgery, and psychiatry · DOI 10.1136/jnnp-2018-320106 · PMID 30967444Open reference}2^{2Neurofilament light chain as a biomarker in neurological disorders.2020 · Journal of neurology, neurosurgery, and psychiatry · DOI 10.1136/jnnp-2018-320106 · PMID 30967444Open reference}3

What p-tau217 can support in trials:

• Baseline enrichment for likely AD-biology participants.^{2Neurofilament light chain as a biomarker in neurological disorders.2020 · Journal of neurology, neurosurgery, and psychiatry · DOI 10.1136/jnnp-2018-320106 · PMID 30967444Open reference}4^{2Neurofilament light chain as a biomarker in neurological disorders.2020 · Journal of neurology, neurosurgery, and psychiatry · DOI 10.1136/jnnp-2018-320106 · PMID 30967444Open reference}5

• Longitudinal biological response in combination with amyloid PET or tau PET imaging.^{2Neurofilament light chain as a biomarker in neurological disorders.2020 · Journal of neurology, neurosurgery, and psychiatry · DOI 10.1136/jnnp-2018-320106 · PMID 30967444Open reference}6^{2Neurofilament light chain as a biomarker in neurological disorders.2020 · Journal of neurology, neurosurgery, and psychiatry · DOI 10.1136/jnnp-2018-320106 · PMID 30967444Open reference}7

• Comparative signal across treatment arms when pre-analytical and assay conditions are tightly standardized.^{2Neurofilament light chain as a biomarker in neurological disorders.2020 · Journal of neurology, neurosurgery, and psychiatry · DOI 10.1136/jnnp-2018-320106 · PMID 30967444Open reference}8^{2Neurofilament light chain as a biomarker in neurological disorders.2020 · Journal of neurology, neurosurgery, and psychiatry · DOI 10.1136/jnnp-2018-320106 · PMID 30967444Open reference}9

What p-tau217 cannot do alone:

• Replace clinical outcomes (function, cognition, quality of life).

• Prove disease modification without convergent imaging/clinical evidence.

• Serve as an approved surrogate endpoint in all settings.^{6Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.2020 · JAMA · DOI 10.1001/jama.2020.12134 · PMID 32722745Open reference}0^{6Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.2020 · JAMA · DOI 10.1001/jama.2020.12134 · PMID 32722745Open reference}1

Practical Implementation Workflow

A clinic-facing workflow for p-tau217 use:

1. Define the question first: screening, differential diagnosis, or treatment-monitoring support.

2. Order p-tau217 with at least one complementary marker (for example NfL or amyloid-related marker panel).^{6Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.2020 · JAMA · DOI 10.1001/jama.2020.12134 · PMID 32722745Open reference}2^{6Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.2020 · JAMA · DOI 10.1001/jama.2020.12134 · PMID 32722745Open reference}3

3. Integrate with syndrome-level exam and MRI before assigning etiologic labels.

4. Escalate to CSF or PET when p-tau217 and phenotype disagree or when major treatment decisions depend on biological certainty.^{6Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.2020 · JAMA · DOI 10.1001/jama.2020.12134 · PMID 32722745Open reference}4^{6Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.2020 · JAMA · DOI 10.1001/jama.2020.12134 · PMID 32722745Open reference}5

5. For CBS/PSP clinics, interpret high p-tau217 as potential AD co-pathology signal, not automatic reclassification.^{6Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.2020 · JAMA · DOI 10.1001/jama.2020.12134 · PMID 32722745Open reference}6^{6Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.2020 · JAMA · DOI 10.1001/jama.2020.12134 · PMID 32722745Open reference}7

Common Pitfalls

• Treating a single p-tau217 value as a diagnosis instead of a probability input.

• Mixing assay platforms during longitudinal follow-up.

• Ignoring pre-analytical variability in sample handling.

• Overgeneralizing AD-derived cutpoints to non-AD syndromes without validation.^{6Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.2020 · JAMA · DOI 10.1001/jama.2020.12134 · PMID 32722745Open reference}8^{6Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.2020 · JAMA · DOI 10.1001/jama.2020.12134 · PMID 32722745Open reference}9

Molecular Biology of p-tau217

Unique Properties

Phosphorylated tau at threonine 217 (p-tau217) demonstrates several distinctive characteristics that make it particularly valuable for Alzheimer’s disease detection:

1. Highest Diagnostic Accuracy: Meta-analyses show p-tau217 has the highest sensitivity and specificity among tau biomarkers for AD

2. Earliest Detectable Change: Elevations detectable 20+ years before clinical symptoms in familial AD

3. Strong Amyloid Correlation: Closely correlates with amyloid burden across disease stages

Structural Context

• Threonine 217 located in the second microtubule-binding repeat (R2) domain^{5Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.2025 · JAMA neurology · DOI 10.1001/jamaneurol.2019.1534 · PMID 31206160Open reference}0

• Phosphorylation alters tau’s interaction with microtubules^{5Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.2025 · JAMA neurology · DOI 10.1001/jamaneurol.2019.1534 · PMID 31206160Open reference}1

• Site is specifically targeted in AD brain tissue^{5Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.2025 · JAMA neurology · DOI 10.1001/jamaneurol.2019.1534 · PMID 31206160Open reference}2

Comparison with p-tau181

Clinical Performance

Alzheimer’s Disease Detection

Core Metrics

• Sensitivity: 90-95% for AD dementia

• Specificity: 85-95% vs. other dementias

• AUC: 0.92-0.97 in validation studies

Early Detection

Preclinical AD

• Elevated 20 years before symptoms in autosomal dominant AD^{5Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.2025 · JAMA neurology · DOI 10.1001/jamaneurol.2019.1534 · PMID 31206160Open reference}3

• Detectable in sporadic AD 10-15 years before onset

• Correlates with amyloid PET positivity before clinical change

MCI Prediction

• High accuracy for predicting MCI-to-AD conversion

• Annual increase ~15-20% in converters^{5Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.2025 · JAMA neurology · DOI 10.1001/jamaneurol.2019.1534 · PMID 31206160Open reference}4

• Superior to p-tau181 for early detection

Differential Diagnosis

• Distinguishes AD from FTD spectrum disorders^{5Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.2025 · JAMA neurology · DOI 10.1001/jamaneurol.2019.1534 · PMID 31206160Open reference}5

• Helps differentiate AD from Lewy body dementia^{5Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.2025 · JAMA neurology · DOI 10.1001/jamaneurol.2019.1534 · PMID 31206160Open reference}6

• Normal levels in vascular dementia without AD co-pathology^{5Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.2025 · JAMA neurology · DOI 10.1001/jamaneurol.2019.1534 · PMID 31206160Open reference}7

Clinical Utility in 2024-2025

Primary Care Integration

Recent studies demonstrate p-tau217’s utility in primary care settings:

• Triage Performance: High negative predictive value enables efficient ruling out of AD in primary care^{5Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.2025 · JAMA neurology · DOI 10.1001/jamaneurol.2019.1534 · PMID 31206160Open reference}8

• Specialist Referral: Elevated p-tau217 values can trigger expedited specialist evaluation

• Workflow Integration: Blood-based testing simplifies the diagnostic pathway

Treatment Response Monitoring

p-tau217 shows promise for tracking therapeutic response:

• Anti-Amyloid Therapies: Leqembi (lecanemab) and Donanemab trials showed p-tau217 reductions correlating with clinical benefit^{5Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.2025 · JAMA neurology · DOI 10.1001/jamaneurol.2019.1534 · PMID 31206160Open reference}9

• Disease Modification Evidence: Slowing of p-tau217 trajectory supports disease modification

• Biomarker-Directed Dosing: Potential for biomarker-guided treatment decisions

Prognostic Applications

• Progression Prediction: Baseline p-tau217 predicts rate of cognitive decline^{7Biomarker modeling of Alzheimer's disease using PET-based Braak staging.2022 · Nature aging · DOI 10.1038/s43587-022-00204-0 · PMID 37118445Open reference}0

• Amyloid PET Correlation: Strong correlation enables stratification without imaging^{7Biomarker modeling of Alzheimer's disease using PET-based Braak staging.2022 · Nature aging · DOI 10.1038/s43587-022-00204-0 · PMID 37118445Open reference}1

• Clinical Trial Enrichment: Widely used for patient selection in recent AD trials

Diagnostic Algorithms

Recommended Workflow

1. First-line: Aβ42/40 ratio (amyloid detection)

2. Second-line: p-tau217 or p-tau181 (tau detection)

3. Third-line: p-tau217 + p-tau231 (disease staging)

Interpretation Matrix

Analytical Methods

Available Assays

Performance Characteristics

• All platforms show excellent correlation (r > 0.95)^{7Biomarker modeling of Alzheimer's disease using PET-based Braak staging.2022 · Nature aging · DOI 10.1038/s43587-022-00204-0 · PMID 37118445Open reference}2

• Lumipulse provides automated clinical solution^{7Biomarker modeling of Alzheimer's disease using PET-based Braak staging.2022 · Nature aging · DOI 10.1038/s43587-022-00204-0 · PMID 37118445Open reference}3

• Simoa enables plasma measurement

• PrecivityAD2 combines p-tau217 with Aβ42/40 ratio for enhanced discrimination

• ALZpath Dx offers single-marker p-tau217 for simplified clinical workflow

Blood vs CSF Comparison

Plasma p-tau217 shows excellent correlation with CSF p-tau217 (r > 0.90), making it suitable as a less invasive alternative when lumbar puncture is contraindicated or impractical.

Disease Staging Applications

Braak Correlation

• p-tau217 correlates with Braak stage (NFT distribution)^{7Biomarker modeling of Alzheimer's disease using PET-based Braak staging.2022 · Nature aging · DOI 10.1038/s43587-022-00204-0 · PMID 37118445Open reference}5

• Elevations track with regional tau pathology^{7Biomarker modeling of Alzheimer's disease using PET-based Braak staging.2022 · Nature aging · DOI 10.1038/s43587-022-00204-0 · PMID 37118445Open reference}6

• Enables in vivo staging of AD severity

Progression Monitoring

• Annual increases of 10-15% in progressive MCI^{7Biomarker modeling of Alzheimer's disease using PET-based Braak staging.2022 · Nature aging · DOI 10.1038/s43587-022-00204-0 · PMID 37118445Open reference}7

• Reflects ongoing tau pathology

• Treatment response marker for anti-tau therapies^{7Biomarker modeling of Alzheimer's disease using PET-based Braak staging.2022 · Nature aging · DOI 10.1038/s43587-022-00204-0 · PMID 37118445Open reference}8

Research Applications

Clinical Trials

• Patient selection for anti-amyloid trials

• Pharmacodynamic marker for tau-targeted drugs^{7Biomarker modeling of Alzheimer's disease using PET-based Braak staging.2022 · Nature aging · DOI 10.1038/s43587-022-00204-0 · PMID 37118445Open reference}9

• Surrogate endpoint for disease modification^{2Neurofilament light chain as a biomarker in neurological disorders.2020 · Journal of neurology, neurosurgery, and psychiatry · DOI 10.1136/jnnp-2018-320106 · PMID 30967444Open reference}00

Biomarker Studies

• Neuropathological validation studies^{2Neurofilament light chain as a biomarker in neurological disorders.2020 · Journal of neurology, neurosurgery, and psychiatry · DOI 10.1136/jnnp-2018-320106 · PMID 30967444Open reference}01

• PET correlation studies

• Genetic modifier studies^{2Neurofilament light chain as a biomarker in neurological disorders.2020 · Journal of neurology, neurosurgery, and psychiatry · DOI 10.1136/jnnp-2018-320106 · PMID 30967444Open reference}02

Comparison with Other Biomarkers

Amyloid Biomarkers

• p-tau217 more specific than Aβ42/40 for AD

• Combined approach provides highest accuracy^{2Neurofilament light chain as a biomarker in neurological disorders.2020 · Journal of neurology, neurosurgery, and psychiatry · DOI 10.1136/jnnp-2018-320106 · PMID 30967444Open reference}03

• p-tau217/Aβ42/40 ratio shows promise

Neurodegeneration Markers

• More specific than total tau for AD

• Earlier elevation than NfL in AD^{2Neurofilament light chain as a biomarker in neurological disorders.2020 · Journal of neurology, neurosurgery, and psychiatry · DOI 10.1136/jnnp-2018-320106 · PMID 30967444Open reference}04

• Independent prognostic value

Limitations and Considerations

Analytical

• Platform-specific cut-offs required^{2Neurofilament light chain as a biomarker in neurological disorders.2020 · Journal of neurology, neurosurgery, and psychiatry · DOI 10.1136/jnnp-2018-320106 · PMID 30967444Open reference}05

• Less standardized than p-tau181^{2Neurofilament light chain as a biomarker in neurological disorders.2020 · Journal of neurology, neurosurgery, and psychiatry · DOI 10.1136/jnnp-2018-320106 · PMID 30967444Open reference}06

• Pre-analytical factors affect results

Clinical

• Elevated in some non-AD conditions^{2Neurofilament light chain as a biomarker in neurological disorders.2020 · Journal of neurology, neurosurgery, and psychiatry · DOI 10.1136/jnnp-2018-320106 · PMID 30967444Open reference}07

• Cannot determine exact disease stage^{2Neurofilament light chain as a biomarker in neurological disorders.2020 · Journal of neurology, neurosurgery, and psychiatry · DOI 10.1136/jnnp-2018-320106 · PMID 30967444Open reference}08

• Limited availability compared to p-tau181^{2Neurofilament light chain as a biomarker in neurological disorders.2020 · Journal of neurology, neurosurgery, and psychiatry · DOI 10.1136/jnnp-2018-320106 · PMID 30967444Open reference}09

Future Directions

Blood-Based Testing

• Plasma p-tau217 now available

• Excellent correlation with CSF p-tau217

• Enables population screening^{2Neurofilament light chain as a biomarker in neurological disorders.2020 · Journal of neurology, neurosurgery, and psychiatry · DOI 10.1136/jnnp-2018-320106 · PMID 30967444Open reference}10

Combination Panels

• p-tau217 + p-tau181 + Aβ42/40^{2Neurofilament light chain as a biomarker in neurological disorders.2020 · Journal of neurology, neurosurgery, and psychiatry · DOI 10.1136/jnnp-2018-320106 · PMID 30967444Open reference}11

• Multi-marker approach for precision medicine^{2Neurofilament light chain as a biomarker in neurological disorders.2020 · Journal of neurology, neurosurgery, and psychiatry · DOI 10.1136/jnnp-2018-320106 · PMID 30967444Open reference}12

• Automated multiplex platforms^{2Neurofilament light chain as a biomarker in neurological disorders.2020 · Journal of neurology, neurosurgery, and psychiatry · DOI 10.1136/jnnp-2018-320106 · PMID 30967444Open reference}13

Emerging Clinical Applications

Primary Care Integration

Blood-based p-tau217 is transitioning from specialized memory clinics to primary care settings:

• Triage Tool: Enables rapid screening of cognitive complaints in primary care

• Specialist Referral: High values can prompt expedited specialist referral

• Monitoring: Serial measurements feasible in routine clinical practice

Clinical Trial Applications

p-tau217 serves multiple roles in clinical trials:

• Patient Enrichment: Selecting amyloid-positive, tau-positive patients for anti-amyloid trials

• Pharmacodynamic Marker: Tracking target engagement of disease-modifying therapies

• Progression Marker: Monitoring disease modification effects over time

Regulatory Landscape

FDA Status

• PrecivityAD2 (C2N Diagnostics): FDA cleared combination test measuring p-tau217 and Aβ42/40 ratio

• ALZpath Dx: CLIA-certified blood test for p-tau217, widely available in US laboratories

International Status

• EU (CE Mark): Multiple p-tau217 assays available as IVD devices

• UK (UKCA): Approved for clinical use

• Japan (PMDA): Lumipulse platform approved for clinical use

Head-to-Head Comparisons

p-tau217 vs p-tau181

p-tau217 vs p-tau231

Mechanistic Insights

Why p-tau217 is Particularly Informative

The threonine-217 phosphorylation site shows exceptional biomarker utility because:

1. Disease-Specific Phosphorylation: T217 is preferentially phosphorylated in AD brain vs. other tauopathies

2. Soluble Species Marker: Captures early soluble oligomeric tau before fibril formation

3. Amyloid Dependency: Rise is amyloid-driven, making it specific to AD biological cascade

4. Longitudinal Tracking: Shows consistent annual increases correlating with disease progression

Relationship to Neurofibrillary Pathology

p-tau217 correlates with ^{2Neurofilament light chain as a biomarker in neurological disorders.2020 · Journal of neurology, neurosurgery, and psychiatry · DOI 10.1136/jnnp-2018-320106 · PMID 30967444Open reference}14^{2Neurofilament light chain as a biomarker in neurological disorders.2020 · Journal of neurology, neurosurgery, and psychiatry · DOI 10.1136/jnnp-2018-320106 · PMID 30967444Open reference}15:

• Braak staging (r = 0.65-0.75)

• Regional tau PET burden

• Neuronal loss in affected regions

• Cognitive decline trajectory

Practical Considerations

Sample Collection Best Practices

1. Fasting: Not required, but consistent timing recommended

2. Tube Type: EDTA plasma or serum acceptable

3. Centrifugation: Within 2 hours of collection, 2000-3000 x g for 10 minutes

4. Storage: -80°C for long-term, -20°C for short-term (< 1 month)

5. Freeze-Thaw: Maximum 3 freeze-thaw cycles recommended

Interpretation Caveats

• Single values should be interpreted probabilistically, not deterministically

• Consider comorbid conditions that may elevate p-tau217 (e.g., brain injury, stroke)

• Age-related changes require age-adjusted reference ranges

• Platform-specific cutoffs must be used

Emerging Research Directions

Point-of-Care Development

• Lateral flow assays under development for rapid p-tau217 testing

• Integrated digital-cognitive biomarker platforms

• Home testing potential for at-risk population monitoring

Standardization Initiatives

• WHO reference material development

• International harmonization across platforms

• External quality assessment programs

Multi-Analyte Panels

• p-tau isoforms (217, 181, 231) combined measurement

• Integration with neurodegeneration markers (NfL, GFAP)

• Proteomic approaches for comprehensive profiling

Allen Brain Atlas Resources

• Allen Brain Atlas - Gene Expression - Search for gene expression data across brain regions

• Allen Brain Atlas - Cell Types - Explore neuronal cell type taxonomy

Recent Advances (2024-2026)

Clinical Validation Studies

Large-scale validation studies have continued to confirm p-tau217 as the leading blood-based biomarker for AD pathology detection:

• Primary care implementation: Studies demonstrated feasibility of p-tau217 screening in primary care settings, with the screen-positive rate of approximately 15-20% in memory clinic populations aligning with expected prevalence^{2Neurofilament light chain as a biomarker in neurological disorders.2020 · Journal of neurology, neurosurgery, and psychiatry · DOI 10.1136/jnnp-2018-320106 · PMID 30967444Open reference}16

• Longitudinal trajectory data: Annual p-tau217 increases of >10% predict conversion from MCI to AD dementia with 85% accuracy. Rate of change provides additional predictive value beyond baseline levels^{2Neurofilament light chain as a biomarker in neurological disorders.2020 · Journal of neurology, neurosurgery, and psychiatry · DOI 10.1136/jnnp-2018-320106 · PMID 30967444Open reference}17

• Combination with GFAP: The combination achieves AUC values of 0.97 for distinguishing AD from non-AD neurodegeneration, outperforming either marker alone

Regulatory Status Update

The regulatory landscape for p-tau217 has evolved significantly:

• FDA clearance path: Multiple p-tau217 assays are under FDA review, with decisions expected 2026-2027. The FDA has published guidance on blood biomarker validation requirements

• Automated platform harmonization: Inter-laboratory coefficients of variation are below 10% for p-tau217 across five major platforms (Roche, Fujirebio, Lumipulse, Abbott, Simoa), meeting clinical chemistry standards

• Clinical guidelines: The Alzheimer’s Association and AAN have published recommendations for blood biomarker use in clinical practice

Population Screening Applications

p-tau217 is now being evaluated for population-based screening:

• DIAN-TU trial network: Data shows p-tau217 can be used in community-based settings with appropriate sample handling

• Ancestry-specific cutoffs: Performance validation across diverse cohorts demonstrates that p-tau217 maintains diagnostic performance across Asian, Black, Hispanic, and non-Hispanic White populations, though ancestry-specific cutoffs are recommended^{2Neurofilament light chain as a biomarker in neurological disorders.2020 · Journal of neurology, neurosurgery, and psychiatry · DOI 10.1136/jnnp-2018-320106 · PMID 30967444Open reference}18

• Health economic modeling: p-tau217 screening in primary care could reduce diagnostic costs by 40-60% compared to current diagnostic pathways

Treatment Monitoring Applications

p-tau217 shows promise as a pharmacodynamic marker:

• Anti-amyloid therapy tracking: Extension studies for lecanemab and donanemab show that p-tau217 trajectory changes with successful amyloid removal

• Disease modification evidence: Patients demonstrating p-tau217 stabilization or reduction show slower cognitive decline

• Trial enrichment: Used for patient selection in prevention trials and as secondary endpoints